Dociparstat Sodium (CX-01) Combined With Standard Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Stephen Marcus, MD
Cantex Pharmaceuticals Inc.
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
23 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- University of California, San Diego, Moores Cancer Center
La Jolla, California, United States
- Colorado Blood Cancer Institute
Denver, Colorado, United States
- George Washington University
Washington D.C., District of Columbia, United States
- Franciscan St. Francis Health
Indianapolis, Indiana, United States
- June E. Nylen Cancer Center
Sioux City, Iowa, United States
- Norton Cancer Institute
Louisville, Kentucky, United States
- Tulane University/tulane Cancer Center
New Orleans, Louisiana, United States
- Karmanos Cancer Institute
Detroit, Michigan, United States
- Allina Health - Virginia Piper Cancer Institute
Minneapolis, Minnesota, United States
- Washington University School of Medicine in St. Louis
St Louis, Missouri, United States
- New Mexico Cancer Care Alliance
Albuquerque, New Mexico, United States
- Northwell Health, Monter Cancer Center
Lake Success, New York, United States
- Montefiore Medical Center
The Bronx, New York, United States
- University of Cincinnati
Cincinnati, Ohio, United States
- Oregon Health & Science University Knight Cancer Institute
Portland, Oregon, United States
- Rhode Island Hospital
Providence, Rhode Island, United States
- Medical University of South Carolina
Charleston, South Carolina, United States
- Avera Cancer Institute
Sioux Falls, South Dakota, United States
- Tennessee Oncology/sarah Cannon Research Institute
Nashville, Tennessee, United States
- Baylor Research Institute/baylor Sammons Cancer Center/baylor University Medical Center
Dallas, Texas, United States
- Methodist Healthcare System of San Antonio
San Antonio, Texas, United States
- Huntsman Cancer Institute
Salt Lake City, Utah, United States
- Lds Hospital
Salt Lake City, Utah, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Aug 2016
- Primary completion
- 30 Jun 2019
- Completion
- 30 Jun 2019
- Last update posted
- 7 Sept 2023
- Registered enrollment
- 75
- Registry id
- NCT02873338
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.